Bear Stearns gives Pfizer outperform rating

Pfizer Inc. was rated at outperform with a price target of $30 by Bear Stearns analyst John Boris on news that the company is considering retaining, spinning or selling its consumer health care business (PCH). Bear Stearns estimates PCH's value at $10 billion, or $1.35 per share, potentially attracting interest from multiple pharmaceutical and consumer strategic buyers. Shares of the New York City pharmaceutical company were down 3 cents, or 0.11%, at $26.34 on volume of 45,826,500 shares versus the three-month running average of 36,429,100 shares. (NYSE: PFE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.